EpCAM expression in the prostate cancer makes the difference in the response to growth factors

Biochemical and Biophysical Research Communications

Volumn 443, Issue 1, 2014, Pages 239-245

  Yoshida, Go J ^a   Saya, Hideyuki ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Cancer stem like cell; EGFR signaling; EpCAM; Heterogeneity; MTOR signaling; Prostate cancer

Indexed keywords

AMINO ACID TRANSPORTER; EPITHELIAL CELL ADHESION MOLECULE; EPITHELIAL GROWTH FACTOR; EPITHELIAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; LAT1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; SOMATOMEDIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER STEM LIKE CELL; CELL HETEROGENEITY; CELL MEMBRANE; CELL SUBPOPULATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; SERUM; SIGNAL TRANSDUCTION; STARVATION;

CANCER STEM-LIKE CELL; EGFR SIGNALING; EPCAM; HETEROGENEITY; MTOR SIGNALING; PROSTATE CANCER;

AMP-ACTIVATED PROTEIN KINASES; ANTIGENS, NEOPLASM; CELL ADHESION MOLECULES; CELL LINE, TUMOR; EPIDERMAL GROWTH FACTOR; HUMANS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; NEOPLASTIC STEM CELLS; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84890860977     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2013.11.093     Document Type: Article

References (33)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics. CA Cancer J. Clin. 2013, 63(2013):11-30.
2. Ilic D., Neuberger M.M., Djulbegovic M., Dahm P. Screening for prostate cancer. Cochrane Database Syst. Rev. 2013, 1:CD004720.
3. Damber J.E. Endocrine therapy for prostate cancer. Acta Oncol. 2005, 44:605-609.
4. Carles J., Castellano D., Climent M.A., Maroto P., Medina R., Alcaraz A. Castration-resistant metastatic prostate cancer: current status and treatment possibilities. Clin. Transl. Oncol. 2012, 14:169-176.
5. Liavag I., Harbitz T.B., Haugen O.A. Latent carcinoma of the prostate. Recent Results Cancer Res. 1972, 39:131-137.
6. Marjanovic N.D., Weinberg R.A., Chaffer C.L. Cell plasticity and heterogeneity in cancer. Clin. Chem. 2013, 59:168-179.
7. Reya T., Morrison S.J., Clarke M.F., Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 2001, 414:105-111.
8. Shah M., Allegrucci C. Stem cell plasticity in development and cancer: epigenetic origin of cancer stem cells. Subcell. Biochem. 2012, 61:545-565.
9. Signoretti S., Loda M. Prostate stem cells: from development to cancer. Semin. Cancer Biol. 2007, 17:219-224.
10. Imrich S., Hachmeister M., Gires O. EpCAM and its potential role in tumor-initiating cells. Cell Adh. Migr. 2012, 6:30-38.
11. Patriarca C., Macchi R.M., Marschner A.K., Mellstedt H. Epithelial cell adhesion molecule expression (CD326) in cancer: a short review. Cancer Treat. Rev. 2012, 38:68-75.
12. Strati A., Markou A., Parisi C., Politaki E., Mavroudis D., Georgoulias V., Lianidou E. Gene expression profile of circulating tumor cells in breast cancer by RT-qPCR. BMC Cancer 2011, 11:422.
13. Spano D., Heck C., De Antonellis P., Christofori G., Zollo M. Molecular networks that regulate cancer metastasis. Semin. Cancer Biol. 2012, 22:234-249.
14. Yoshida G.J., Saya H. Encounter of cancer cells with bone. The significance of cancer stem cells and epithelial-mesenchymal transition in tumor invasion and metastasis. Clin. Calcium 2011, 21:411-417.
15. Tsuji T., Ibaragi S., Hu G.F. Epithelial-mesenchymal transition and cell cooperativity in metastasis. Cancer Res. 2009, 69:7135-7139.
16. Ni J., Cozzi P.J., Duan W., Shigdar S., Graham P.H., John K.H., Li Y. Role of the EpCAM (CD326) in prostate cancer metastasis and progression. Cancer Metastasis Rev. 2012, 31:779-791.
17. Aguirre-Ghiso J.A. Models, mechanisms and clinical evidence for cancer dormancy. Nat. Rev. Cancer 2007, 7:834-846.
18. Nagano O., Okazaki S., Saya H. Redox regulation in stem-like cancer cells by CD44 variant isoforms. Oncogene 2013, 32(44):5191-5198.
19. Yoshida G.J., Saya H. Three-dimensional culture of sebaceous gland cells revealing the role of prostaglandin E-induced activation of canonical Wnt signaling. Biochemical and Biophysical Research Communications Volume 2013, 438(4):640-646.
20. Jiang B., Mason J., Jewett A., Qian J., Ding Y., Cho W.C., Zhang X., Man Y.G. Cell budding from normal appearing epithelia: a predictor of colorectal cancer metastasis?. Int. J. Biol. Sci. 2013, 9:119-133.
21. Gostner J.M., Fong D., Wrulich O.A., Lehne F., Zitt M., Hermann M., Krobitsch S., Martowicz A., Gastl G., Spizzo G. Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer 2011, 11:45.
22. Maetzel D., Denzel S., Mack B., Canis M., Went P., Benk M., Kieu C., Papior P., Baeuerle P.A., Munz M., Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat. Cell Biol. 2009, 11:162-171.
23. Kaighn M.E., Narayan K.S., Ohnuki Y., Lechner J.F., Jones L.W. Establishment and characterization of a human prostatic carcinoma cell line (PC-3). Invest. Urol. 1979, 17:16-23.
24. Stone K.R., Mickey D.D., Wunderli H., Mickey G.H., Paulson D.F. Isolation of a human prostate carcinoma cell line (DU 145). Int. J. Cancer 1978, 21:274-281.
25. Duan W.R., Garner D.S., Williams S.D., Funckes-Shippy C.L., Spath I.S., Blomme E.A. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J. Pathol. 2003, 199:221-228.
26. Linder S., Havelka A.M., Ueno T., Shoshan M.C. Determining tumor apoptosis and necrosis in patient serum using cytokeratin 18 as a biomarker. Cancer Lett. 2004, 214:1-9.
27. Hardie D.G. AMP-activated protein kinase: an energy sensor that regulates all aspects of cell function. Genes Dev. 2011, 25:1895-1908.
28. Hardie D.G., Alessi D.R. LKB1 and AMPK and the cancer-metabolism link - ten years after. BMC Biol. 2013, 11:36.
29. Liang J., Shao S.H., Xu Z.X., Hennessy B., Ding Z., Larrea M., Kondo S., Dumont D.J., Gutterman J.U., Walker C.L., Slingerland J.M., Mills G.B. The energy sensing LKB1-AMPK pathway regulates p27(kip1) phosphorylation mediating the decision to enter autophagy or apoptosis. Nat. Cell Biol. 2007, 9:218-224.
30. Hardie D.G., Ross F.A., Hawley S.A. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 2012, 13:251-262.
31. Christensen H.N. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol. Rev. 1990, 70:43-77.
32. Kaira K., Oriuchi N., Takahashi T., Nakagawa K., Ohde Y., Okumura T., Murakami H., Shukuya T., Kenmotsu H., Naito T., Kanai Y., Endo M., Kondo H., Nakajima T., Yamamoto N. L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res. 2011, 31:4075-4082.
33. Lin J., Raoof D.A., Thomas D.G., Greenson J.K., Giordano T.J., Robinson G.S., Bourner M.J., Bauer C.T., Orringer M.B., Beer D.G. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 2004, 6:74-84.